Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Yalelaan 62
The company trades on NASDAQ exchange. The company headquarter is located in Netherlands. The company was established in the 2003.| Ticker | MRUS |
| Long Name | Merus N.V. |
| Short Name | Merus |